A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs EFT 508 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 06 Jun 2017 Preliminary results (n=28) assessing the safety and tolerability of eFT508 in patients with advanced solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2017 Results published in an Effector Therapeutics media release.
- 05 Jun 2017 According to an Effector Therapeutics media release, initial phase II efficacy data is anticipated in 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History